The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade

Neuropharmacology

Volumn 45, Issue 2, 2003, Pages 174-181

  Leriche, Ludovic ^a   Schwartz, Jean Charles ^a,b   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antipsychotic drug; BP 897; D3 receptor deficient mice; Dizocilpine; Nafadotride

Indexed keywords

BP 897; CLOZAPINE; DIZOCILPINE; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NAFADOTRIDE; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; DOPAMINE 2 RECEPTOR; DRD3 PROTEIN, MOUSE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; HYPERKINESIA; MOTOR ACTIVITY; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HYPERKINESIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0037493457     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00145-X     Document Type: Article

References (44)

1. 3 receptor gene is associated with hyperactivity in mice. Proceeding of the National Academy of Sciences of the USA. 93:1996;1945-1949.
2. Andiné P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., Sandberg M. Characterization of MK-801-induced behavior as a putative rat model of psychosis. The Journal of Pharmacology and Experimental Therapeutics. 290:1999;1393-1408.
3. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proceeding of the National Academy of Sciences of the USA. 94:1997;3363-3367.
4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
5. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. Journal of Neural Transmission. 75:1989;221-226.
6. Cosgrove J., Newell T.G. Recovery of neuropsychological function during reduction in use of phencyclidine. Journal of Clinical Psychology. 47:1991;159-169.
7. 3 receptors expressed by all mesencephalic dopamine neurons. Journal of Neuroscience. 20:2000;8677-8684.
8. 3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. American Journal of Medical Genetic [Neuropsychiatric Genetics]. 81:1998;318-322.
9. Fessler R.G., Sturgeon R.D., Meltzer H.Y. Effects of phencyclidine and methylphenidate on d-amphetamine-induced behaviors in reserpine-pretreated rats. Pharmacology Biochemistry and Behavior. 13:1980;835-842.
10. Freeman A.S., Bunney B.S. The effects of phencyclidine and n-allynomethazocine on midbrain dopamine dopamine neuronal activity. European Journal of Pharmacology. 104:1984;187.
11. French E.D., Pilapil C., Quirion R. Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. European Journal of Pharmacology. 116:1985;1-9.
12. Grenhoff J., Nisell M., Ferre S., Aston-jones G., Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. Journal of Neural Transmission. 93:1993;11-25.
13. 3 receptors and use of antipsychotics in patients with schizophrenia. Archives of General Psychiatry. 54:1997;225-232.
14. Ital T., Keskiner A., Kiremitci N., Holde J.M.C. Effect of phencyclidine in chronic schizophrenics. Canadian Psychiatric Association Journal. 12:1967;209-212.
15. Janowsky D.S., Davis J.M. Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. Archives of General Psychiatry. 33:1976;304-308.
16. Javitt D.C., Zukin S.R. Recent advance in the phencyclidine model of schizophrenia. American Journal of Psychiatry. 148:1991;1301-1308.
17. Jentsch J., Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
18. 3 receptor in reactivity to cocaine-associated cues in mice. European Journal of Neuroscience. 15:2002;2016-2026.
19. 2 dopamine receptors by nafadotride. Neuropsychopharmacology. 17:1997;67-71.
20. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelly R. Study of a new schizophrenic-like drug: Sernyl. Archives of Neurology and Psychiatry. 81:1959;363-369.
21. Mathé J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. European Journal of Pharmacology. 309:1996;1-11.
22. Meller E., Helmer-Matyjek E., Bohmaker K., Adler C.H., Friedhoff A.J., Golstein M. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. European Journal of Pharmacology. 123:1986;311-314.
23. Meltzer H.Y. An overview of the mechanism of action of clozapine. Journal of Clinical Psychiatry. 55:1994;47-52.
24. 3-receptors: I receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. The Journal of Pharmacology and Experimental Therapeutics. 293:2000;1048-1062.
25. Murase S., Mathé J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. Journal of Neural Transmission. 91:1992;13-25.
26. Murray T.F., Horita A. Phencyclidine-induced stereotyped behavior in rat: dose-response effects and antagonism by neuroleptics. Life Sciences. 24:1979;2217-2225.
27. Ninan I., Kulkarni S.K. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. European Journal of Pharmacology. 368:1999;1-7.
28. Ögren S.O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology. 11:1994;167-177.
29. 2 receptor antagonism reduces hyperactivity induced by amphetamine. Pharmacology Biochemistry and Behavior. 63:1999;237-243.
30. 3 receptors in thermoregulation: a reappraisal. Neuroreport. 11:2000;221-225.
31. 3 receptor agonist. Nature. 400:1999;371-375.
32. Prisco S., Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. British Journal of Pharmacology. 116:1995;1923-1931.
33. 3 receptor antagonist, SB-277011-A. The Journal of Pharmacology and Experimental Therapeutics. 294:2000;1154-1165.
34. 3 receptor antagonist, activates locomotion in rodents. The Journal of Pharmacology and Experimental Therapeutics. 275:1995;1239-1246.
35. Schaefer G.J., Michael R.P. Drug interactions on spontaneous locomotor activity in rats. Neuroleptics and amphetamine-induced hyperactivity. Neuropharmacology. 23:1984;909-914.
36. 3 receptors in vivo. European Journal of Pharmacology. 218:1992;373-375.
37. 3 receptor in schizophrenia and in antipsychotic drug actions. Brain Research Reviews. 31:2000;277-287.
38. Snyder S.H. Psychogenic drugs as models of schizophrenia. Neuropsychopharmacology. 1:1988;197-199.
39. Snyder S.H. Phencyclidine. Nature. 285:1980;355-356.
40. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
41. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drug. Brain Research Reviews. 31:2000;320-329.
42. Wong E.H.F., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsivant MK-801 is a potent N-methyl-d-aspartate antagonist. Proceeding of the National Academy of Sciences of the USA. 83:1986;7104-7108.
43. 3 receptor-selective agonists and antagonists. Synapse. 31:1999;210-215.
44. 3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology. 41:2001;351-359.